These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32562083)

  • 21. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
    Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
    Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
    Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
    Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18β-Glycyrrhetinic acid synergizes with enzalutamide to counteract castration-resistant prostate cancer by inhibiting OATP2B1 uptake of dehydroepiandrosterone sulfate.
    Lu T; Liao B; Lin R; Meng C; Huang P; Wang C; Liu F; Xia C
    Eur J Pharmacol; 2024 Nov; 983():176995. PubMed ID: 39277096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
    Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
    Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
    Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
    Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
    Zhang B; Zhang M; Yang Y; Li Q; Yu J; Zhu S; Niu Y; Shang Z
    Oncogene; 2022 Jan; 41(3):387-399. PubMed ID: 34759344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.
    Ardiani A; Farsaci B; Rogers CJ; Protter A; Guo Z; King TH; Apelian D; Hodge JW
    Clin Cancer Res; 2013 Nov; 19(22):6205-18. PubMed ID: 24048332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.
    Calcinotto A; Spataro C; Zagato E; Di Mitri D; Gil V; Crespo M; De Bernardis G; Losa M; Mirenda M; Pasquini E; Rinaldi A; Sumanasuriya S; Lambros MB; Neeb A; Lucianò R; Bravi CA; Nava-Rodrigues D; Dolling D; Prayer-Galetti T; Ferreira A; Briganti A; Esposito A; Barry S; Yuan W; Sharp A; de Bono J; Alimonti A
    Nature; 2018 Jul; 559(7714):363-369. PubMed ID: 29950727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ; Morgans AK; Constantinovici N; Khan N; Khan J; Chen G; Hlebec V; Shore ND
    JAMA Netw Open; 2024 Aug; 7(8):e2429783. PubMed ID: 39190308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
    Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
    Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of Long Noncoding RNA
    Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
    Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
    Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
    Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
    Masoodi KZ; Eisermann K; Yang Z; Dar JA; Pascal LE; Nguyen M; O'Malley K; Parrinello E; Feturi FG; Kenefake AN; Nelson JB; Johnston PA; Wipf P; Wang Z
    Endocrinology; 2017 Oct; 158(10):3152-3161. PubMed ID: 28977599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models.
    Schmidt KT; Chau CH; Strope JD; Huitema ADR; Sissung TM; Price DK; Figg WD
    Mol Cancer Ther; 2021 May; 20(5):915-924. PubMed ID: 33632874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repression of SLC22A3 by the AR-V7/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer.
    Seo E; Jee B; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Kang M
    FEBS J; 2023 Mar; 290(6):1645-1662. PubMed ID: 36254631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression.
    Consiglio CR; Udartseva O; Ramsey KD; Bush C; Gollnick SO
    Cancer Immunol Res; 2020 Sep; 8(9):1215-1227. PubMed ID: 32661092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.